Another US Humira Biosimilar Approved As Formularies Offer Access

While Alvotech And Stada Broaden Reach Of Higher-Strength Adalimumab In Europe

14 Dec 2022

As Fresenius Kabi receives US FDA approval for its Idacio rival to Humira, positive developments are being seen in terms of adding adalimumab biosimilars to local formularies. Meanwhile, in Europe Stada and Alvotech have broadened access to their Hukyndra high-concentration version.

Fresenius Kabi has received US approval for its Idacio biosimilar • Source: Shutterstock

The latest approval for a Humira (adalimumab) biosimilar has been issued by the US Food and Drug Administration, this time for Fresenius Kabi’s Idacio (adalimumab-aacf) version of the top-selling biologic that is due to face US competition in 2023.

Fresenius said that Idacio – a citrate-free 40mg/0.8ml formulation of adalimumab that will be available in both a self-administered pre-filled...